The effect of desmopressin on reducing blood loss in children with congenital cyanotic heart disease undergoing cardiopulmonary bypass

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR202004798675261

Enrollment

Registered

2020-04-24

Start date

2020-04-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery Paediatrics Anaesthesia

Interventions

placebo control group

Desmopressin group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: This study will be conducted on a total of 52 patients with CCHD undergoing CPB of either sex with their age ranging from 3 to 72 month.

Exclusion criteria

Exclusion criteria: Patients will be excluded from the current study in case of refusal of their guardians, redo cardiac surgery, pre existing coagulopathy, hepatic or renal dysfunction and history of allergy to desmopressin.

Design outcomes

Primary

Measure	Time frame
the total amount of blood loss drained through mediastinal and pleural drainage tubes during the first 24 postoperative hours	—

Secondary

Measure	Time frame
rate RBCS transfusion, hours of mechanical ventilation, duration of intensive care unit, and hospital stay	—

Countries

Egypt

Contacts

Public ContactNabil Abd Elraouf

Professor of anesthesia and surgical Intensive care at faculty of medicine Mansoura university

nabil_abdelraouf@yahoo.com+201001538648

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026